No Q2 Revenues for Compugen | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Compugen today reported no revenues for its second quarter, down from $800,000 a year ago.

The company's revenues comprise mainly of research fees and milestone and do not include government grants, which Compugen records as a reduction of R&D costs.

For the three months ended June 30, net loss totaled $2.2 million, or $.06 per share, up 146 percent from a net loss of $896,000, or $.03 per share a year ago.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: deletion of one microRNA allows pluripotent stem cells to form embryonic and non-embryonic lineages, and more.

Arizona is planning to sue Theranos for "deceptive acts" and misrepresentations of its "capabilities and operation."

If confirmed as Department of Health and Human Services Secretary, Tom Price says he will divest himself of certain holdings, according to Stat News.

Oliver Smithies, who won the Nobel Prize in 2007, has died, the New York Times reports.